Immune effectors required for the therapeutic activity of vorinostat

References

• Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12:1247 - 52; http://dx.doi.org/10.1634/theoncologist.12-10-1247; PMID: 17962618
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109:31 - 9; http://dx.doi.org/10.1182/blood-2006-06-025999; PMID: 16960145
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25:3109 - 15; http://dx.doi.org/10.1200/JCO.2006.10.2434; PMID: 17577020
   PubMed Web of Science ®Google Scholar
• Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A 2007; 104:8071 - 6; http://dx.doi.org/10.1073/pnas.0702294104; PMID: 17470784
   PubMed Web of Science ®Google Scholar
• Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A, Bhadri VA, Szymanska B, Geninson G, Magistroni V, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010; 116:3013 - 22; http://dx.doi.org/10.1182/blood-2010-05-284968; PMID: 20647567
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74 - 88; http://dx.doi.org/10.1016/j.immuni.2013.06.014; PMID: 23890065
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Christiansen AJ, West A, Banks KM, Haynes NM, Teng MW, Smyth MJ, Johnstone RW. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A 2011; 108:4141 - 6; http://dx.doi.org/10.1073/pnas.1011037108; PMID: 21368108
   PubMed Web of Science ®Google Scholar
• West AC, Christiansen AJ, Smyth MJ, Johnstone RW. The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. Oncoimmunology 2012; 1:377 - 9; http://dx.doi.org/10.4161/onci.18804; PMID: 22737621
   PubMed Web of Science ®Google Scholar
• Verbrugge I, Galli M, Smyth MJ, Johnstone RW, Haynes NM. Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies. Oncoimmunology 2012; 1:1629 - 31; http://dx.doi.org/10.4161/onci.21652; PMID: 23264917
   PubMed Web of Science ®Google Scholar
• West AC, Mattarollo SR, Shortt J, Cluse LA, Christiansen AJ, Smyth MJ, Johnstone RW. An intact immune system is required for the anti-cancer activities of histone deacetylase inhibitors. Cancer Res 2013; Forthcoming http://dx.doi.org/10.1158/0008-5472.CAN-13-0890; PMID: 24158093
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151 - 60; http://dx.doi.org/10.1038/nrclinonc.2010.223; PMID: 21364688
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N, Schlemmer FD, Menger L, Sukkurwala AQ, Adjemian S, et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology 2012; 1:271 - 8; http://dx.doi.org/10.4161/onci.18684; PMID: 22737602
   PubMed Web of Science ®Google Scholar
• Gupta A, Sharma A, von Boehmer L, Surace L, Knuth A, van den Broek M. Radiotherapy supports protective tumor-specific immunity. Oncoimmunology 2012; 1:1610 - 1; http://dx.doi.org/10.4161/onci.21478; PMID: 23264910
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51 - 72; http://dx.doi.org/10.1146/annurev-immunol-032712-100008; PMID: 23157435
   PubMed Web of Science ®Google Scholar
• Guillot F, Boutin B, Blanquart C, Fonteneau JF, Robard M, Grégoire M, Pouliquen D. Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth. Vaccine 2011; 29:5534 - 43; http://dx.doi.org/10.1016/j.vaccine.2011.05.029; PMID: 21619908
   PubMed Web of Science ®Google Scholar
• Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Sukkurwala AQ, Michaud M, Galluzzi L, Zitvogel L, et al. Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology 2012; 1:1640 - 2; http://dx.doi.org/10.4161/onci.21684; PMID: 23264921
   PubMed Web of Science ®Google Scholar
• Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012; 4:143ra99; http://dx.doi.org/10.1126/scitranslmed.3003807; PMID: 22814852
   PubMed Web of Science ®Google Scholar
• Hannani D, Locher C, Yamazaki T, Colin-Minard V, Vetizou M, Aymeric L, Viaud S, Sanchez D, Smyth MJ, Bruhns P, et al. Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ 2013; Forthcoming http://dx.doi.org/10.1038/cdd.2013.60; PMID: 23744294
   PubMed Web of Science ®Google Scholar
• Michaud M, Sukkurwala AQ, Martins I, Shen S, Zitvogel L, Kroemer G. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology 2012; 1:393 - 5; http://dx.doi.org/10.4161/onci.19070; PMID: 22737627
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179 - 88; http://dx.doi.org/10.4161/onci.1.2.19026; PMID: 22720239
   PubMed Web of Science ®Google Scholar
• Schmudde M, Braun A, Pende D, Sonnemann J, Klier U, Beck JF, Moretta L, Bröker BM. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett 2008; 272:110 - 21; http://dx.doi.org/10.1016/j.canlet.2008.06.027; PMID: 18718708
   PubMed Web of Science ®Google Scholar
• Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 2013; 122:684 - 93; http://dx.doi.org/10.1182/blood-2013-02-482513; PMID: 23801635
   PubMed Web of Science ®Google Scholar
• Lucas JL, Mirshahpanah P, Haas-Stapleton E, Asadullah K, Zollner TM, Numerof RP. Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol 2009; 257:97 - 104; http://dx.doi.org/10.1016/j.cellimm.2009.03.004; PMID: 19358983
   PubMed Web of Science ®Google Scholar
• Akimova T, Ge G, Golovina T, Mikheeva T, Wang L, Riley JL, Hancock WW. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 2010; 136:348 - 63; http://dx.doi.org/10.1016/j.clim.2010.04.018; PMID: 20478744
   PubMed Web of Science ®Google Scholar
• de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010; 138:583 - 94; http://dx.doi.org/10.1053/j.gastro.2009.10.037; PMID: 19879272
   PubMed Web of Science ®Google Scholar
• Shen L, Pili R. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology 2012; 1:948 - 50; http://dx.doi.org/10.4161/onci.20306; PMID: 23162767
   PubMed Web of Science ®Google Scholar
• Ogbomo H, Michaelis M, Kreuter J, Doerr HW, Cinatl J Jr.. Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett 2007; 581:1317 - 22; http://dx.doi.org/10.1016/j.febslet.2007.02.045; PMID: 17349632
   PubMed Web of Science ®Google Scholar
• Schmudde M, Friebe E, Sonnemann J, Beck JF, Bröker BM. Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions. Cancer Lett 2010; 295:173 - 81; http://dx.doi.org/10.1016/j.canlet.2010.02.024; PMID: 20346580
   PubMed Web of Science ®Google Scholar
• Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E, Maeda Y, Tawara I, Krijanovski O, Gatza E, et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008; 118:2562 - 73; PMID: 18568076
   PubMed Web of Science ®Google Scholar
• Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA, Ferrara JL. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 2004; 101:3921 - 6; http://dx.doi.org/10.1073/pnas.0400380101; PMID: 15001702
   PubMed Web of Science ®Google Scholar
• Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC, et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther 2013; 21:887 - 94; http://dx.doi.org/10.1038/mt.2012.265; PMID: 23295947
   PubMed Web of Science ®Google Scholar
• Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A, Hodges E, Vermeer M, Packham G. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol 2011; 162:1590 - 602; http://dx.doi.org/10.1111/j.1476-5381.2010.01188.x; PMID: 21198545
   PubMed Web of Science ®Google Scholar
• Stephen S, Morrissey KA, Benoit BM, Kim EJ, Vittorio CC, Nasta SD, Showe LC, Wysocka M, Rook AH. Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma. Am J Hematol 2012; 87:226 - 8; http://dx.doi.org/10.1002/ajh.22231; PMID: 22189940
   PubMed Web of Science ®Google Scholar
• Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691 - 701; http://dx.doi.org/10.1084/jem.20050915; PMID: 16365148
   PubMed Web of Science ®Google Scholar
• Paget C, Duret H, Ngiow SF, Kansara M, Thomas DM, Smyth MJ. Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma. Oncoimmunology 2012; 1:1313 - 22; http://dx.doi.org/10.4161/onci.21680; PMID: 23243595
   PubMed Web of Science ®Google Scholar
• Fridman WH, Galon J, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011; 71:5601 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-11-1316; PMID: 21846822
   PubMed Web of Science ®Google Scholar
• Schmidt M, Micke P, Gehrmann M, Hengstler JG. Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors. Oncoimmunology 2012; 1:1156 - 8; http://dx.doi.org/10.4161/onci.21653; PMID: 23170262
   PubMed Web of Science ®Google Scholar
• Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, et al. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology 2012; 1:432 - 40; http://dx.doi.org/10.4161/onci.19545; PMID: 22754761
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Nelson BH. Tumor-infiltrating B cells and T cells: Working together to promote patient survival. Oncoimmunology 2012; 1:1623 - 5; http://dx.doi.org/10.4161/onci.21650; PMID: 23264915
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323 - 43; http://dx.doi.org/10.4161/onci.22009; PMID: 23243596
   PubMed Web of Science ®Google Scholar
• Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11 - 26; http://dx.doi.org/10.1016/j.immuni.2013.07.008; PMID: 23890060
   PubMed Web of Science ®Google Scholar
• Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro M, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700 - 7; http://dx.doi.org/10.1038/nm.2366; PMID: 21552268
   PubMed Web of Science ®Google Scholar